Navigation Links
Bio-Identical Hormone Menopause Doctor Responds to Recent FDA News About Estriol
Date:1/16/2008

Cheryle R. Hart, M.D. Clarifies Previous Statement on 1/11/08

SPOKANE, Wash., Jan. 16 /PRNewswire/ -- On January 9, 2008 the FDA raised the issue regarding the use of estriol in compounded hormone replacement therapy. While awaiting further clarification, Dr. Hart suspended prescribing estriol in her medical practice. Cheryle Hart, M.D. is Mayo Clinic trained and Board certified in Ob/Gyn and founded what is now Hormones by Hart in 1997. She is also the medical director of Hormones by Hart.

Dr. Hart has been discussing this issue with medical experts in hormone replacement therapy and with some of the most experienced compounding pharmacies across the U.S. "I have learned that compounded hormone prescriptions containing estriol have been and continue to be prescribed as an important part of Hormone Replacement Therapy (HRT) throughout the United States," says Dr. Hart. The continuation of such compounding remains the subject of a major dispute between compounding pharmacies and the FDA.

The International Academy of Compounding Pharmacists (IACP) -- who represents thousands of compounding pharmacies -- says that the situation with estriol is comparable to many commonly prescribed drugs. While estriol was never formally approved by the FDA, it has a monograph from the U.S. Pharmacopeia (USP) prior to 1997. When Congress passed the FDA Modernization Act in 1997, Congress clearly indicated that drugs with a USP monograph could still be compounded when prescribed by a licensed medical practitioner.

"With this new information and clarification from the IACP, I am updating my previous intentions about prescribing compounds containing estriol," says Dr. Hart. "Until the courts give us the final word on this subject, I will continue to prescribe estriol as an important part of the total hormone replacement therapy for my patients -- whom I have found to benefit from its use. I want my patients to know that all of their prescription hormones are still going to be available," promises Cheryle R. Hart, M.D.

If you would like to let the FDA know how you feel, please go to their comment website at: http://www.fda.gov/cder/comment.htm

IACP Reply to FDA News on BHRT: http://www.iacprx.org/

Statement From The American Pharmacists Association Regarding FDA's Action http://www.medicalnewstoday.com/articles/93953.php

Original FDA News Release January 9, 2008: http://www.fda.gov/bbs/topics/NEWS/2008/NEW01772.html


'/>"/>
SOURCE Cheryle R. Hart, M.D.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bio-Identical Hormone Menopause Doctor Responds to Outrageous FDA News
2. Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device
3. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
4. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
5. Medical Breakthrough ... Doctor Discovers Penetrating Carrier That Eradicates Fungus
6. Patient Treatment for Bipolar Disorder Varies Depending on Doctor Specialty; Well Designed Clinical Trials May Be The Answer
7. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
8. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
9. Michigan Catholic Conference Responds to Formation of Embryonic Stem Cell Research Ballot Committee
10. Updated Drug Development Scrip Report Responds to the Pharma Industrys Major Changes
11. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... 2016 , ... Global Stem Cells Group, has ... The new facility will provide advanced protocols and state-of-the-art techniques in cellular medicine, ... , The new GSCG clinic is headed by four prominent Ecuadorian physicians, including ...
(Date:2/10/2016)... NX Prenatal Inc., a US based ... for early warning of adverse pregnancy outcomes, announced ... by Dr. Thomas McElrath of Brigham ... Medicine,s (SMFM) annual meeting held in ... The presentation reported initial positive top-line results regarding ...
(Date:2/10/2016)... 10, 2016  Allergan plc (NYSE: AGN ) ... Brent Saunders , Allergan,s CEO and President, will be ... session at the RBC Capital Markets Healthcare Conference on ... The New York Palace Hotel in New ... live and can be accessed on Allergan,s Investor Relations ...
(Date:2/10/2016)... ... February 10, 2016 , ... LATHAM, NEW YORK... Marktech Optoelectronics ... Photonics West conference in San Francisco’s Moscone Center from February 16-18, 2016, and ... , These latest InGaAs PIN diode standard packages feature a TO-46 metal can ...
Breaking Biology Technology:
(Date:1/28/2016)... SAN JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: ... financial results for its second quarter ended December 31, 2015. ... the second quarter of fiscal 2016 increased 2 percent compared to ... the second quarter of fiscal 2016 was $35.0 million, or $0.93 ... Non-GAAP net income for the first quarter of fiscal 2016 ...
(Date:1/22/2016)... http://www.researchandmarkets.com/research/p74whf/global_biometrics ) ... "Global Biometrics Market in Retail Sector 2016-2020" ... --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has announced the ... in Retail Sector 2016-2020" report to ... and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has announced ...
(Date:1/18/2016)... JOSE, Calif. , Jan. 18, 2016 /PRNewswire/ ... security software that simplifies the use and access ... technology and go-to-market partnership with American Cyber.  ... Cyber brings extensive experience leading transformational C4ISR and ... implementing and integrating the latest proven technology solutions," ...
Breaking Biology News(10 mins):